SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

mazdutide

OPK·OPKO Health, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (China NMPA)
Time to market
Already approved and commercializing in China (June 2025 for weight management, September 2025 for type 2 diabetes). No US FDA filing has been announced; US approval is estimated in the 2027-2028 window if Eli Lilly initiates and completes global Phase 3 trials.
Why 3/10
No hard binary catalyst is scheduled for mazdutide in the next ~12 months. The drug is already approved and commercializing in China (June 2025 for weight management, September 2025 for type 2 diabetes). OPKO is a passive royalty holder, not the developer. A US FDA filing by Eli Lilly is not expected before 2027-2028. Without a dated PDUFA, pivotal readout or AdComm, the impactScore is capped at 3-5 per the rubric; the score of 3 reflects that mazdutide is an approved, commercial-stage asset with no pending regulatory decision and that OPKO's exposure is limited to a royalty stream that has already been partially monetized.
Actionable Insight NEUTRAL

Watch OPKO's quarterly royalty revenue from mazdutide as a gauge of China commercial uptake. Innovent's product revenue grew over 40% YoY in Q3 2026, but OPKO's specific royalty share is not separately disclosed. No near-term binary catalyst exists for this asset; the next potential catalyst would be Eli Lilly announcing a US Phase 3 program or FDA filing, which is not expected before 2027-2028.

Price Chart

Loading chart...

Executive Summary

Mazdutide (brand name Xinermei in China, development codes IBI362/LY3305677) is a once-weekly GLP-1/glucagon dual receptor agonist for weight management and type 2 diabetes. It was developed by Eli Lilly and licensed to Innovent Biologics for China, where it received NMPA approval in June 2025 (weight management) and September 2025 (type 2 diabetes). Phase 3 trials (GLORY-1, GLORY-2) showed 14-20% weight loss. The drug is not FDA-approved in the US. OPKO Health (NASDAQ: OPK) holds a royalty interest through a licensing agreement with Eli Lilly, recording its first mazdutide royalty revenue in 2025 ($4.3M in Q4 2025). In August 2026, OPKO raised $125M in senior secured notes backed by future mazdutide royalty payments, capping repayment at 1.5x funded while retaining long-term upside. OPKO is a passive royalty recipient, not the drug's developer or commercializer.

How It Works

Mazdutide is a once-weekly injectable drug that activates two natural hormone receptors at the same time: GLP-1 (which suppresses appetite and slows digestion) and glucagon (which increases energy expenditure and fat burning). This dual mechanism is designed to produce greater weight loss than drugs that only target GLP-1 alone.

Trial Status

Mazdutide is approved in China for both chronic weight management (June 2025) and type 2 diabetes (September 2025). Phase 3 trials GLORY-1 (NEJM 2025, 14% weight loss at 6mg) and GLORY-2 (JAMA 2026, 18.55% weight loss at 9mg) were completed in Chinese adults. The DREAMS-3 Phase 3 head-to-head trial versus semaglutide showed mazdutide superiority on glycemic control and weight loss (presented at ADA 2026). A US Phase 2 trial in obesity/overweight completed and was published in The Lancet Diabetes & Endocrinology (2026). A Phase 2 trial in alcohol use disorder (NCT06817356) completed in May 2026. No US Phase 3 program has been announced by Eli Lilly.

The Two-Sided Case

▲ Bull Case5
Mazdutide is the world's first approved GLP-1/glucagon dual agonist, a novel mechanism that showed 14-20% weight loss in Phase 3 China trials (GLORY-1 and GLORY-2), potentially differentiating it from single-mechanism competitors.
China approved mazdutide for both weight management (June 2025) and type 2 diabetes (September 2025), giving it a large addressable market in a country with high obesity and diabetes prevalence.
Innovent reported Q3 2026 product revenue exceeding RMB 4.7 billion (over 40% YoY growth), with mazdutide cited as a key growth driver, suggesting accelerating commercial uptake.
OPKO's $125 million royalty-backed financing (August 2026) was non-dilutive, and the company retains long-term royalty economics beyond the 1.5x repayment cap, providing leveraged exposure to mazdutide's China sales growth.
Analyst consensus on OPK is bullish: 8 analysts rate it Buy/Strong Buy (mean target $4.15 vs ~$1.74 current price, implying ~137% upside), and the stock has seen multiple institutional accumulations in Q2-Q3 2026.
▼ Bear Case5
OPKO is a passive royalty holder, not the developer; Eli Lilly and Innovent control commercialization, pricing and supply, leaving OPKO with no operational influence over mazdutide's success.
Royalty revenue is still small: Q4 2025 generated only $4.3 million for OPKO, a negligible contribution relative to the company's overall revenue and operating losses.
OPKO has already borrowed $125 million against future mazdutide royalty streams (August 2026), capping total repayment at 1.5x funded, which limits the upside OPKO can capture from the royalty stream.
Mazdutide is only approved in China and not filed with the FDA; a US approval pathway is years away and uncertain.
China's GLP-1 market is becoming intensely competitive with domestic and imported alternatives (semaglutide, tirzepatide, and other dual agonists), which could pressure mazdutide's commercial trajectory.

Upcoming Catalysts

  • Quarterly mazdutide royalty revenue disclosures in OPKO earnings reports (next: Q4 2026, expected early 2027)
  • Potential Eli Lilly announcement of US Phase 3 program or FDA filing timeline (no date confirmed; estimated 2027-2028)
  • China commercial sales growth trajectory as Innovent continues mazdutide rollout

Source Filing

The SecBot filing or press-release report that triggered this drug report:

OPKO Health, Inc. PRESS-RELEASE OPK ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 link.springer.com3 opko.com4 opko.com5 prnewswire.com6 prnewswire.com7 biospace.com8 www1.hkexnews.hk9 jamanetwork.com10 nejm.org11 en.innoventbio.com12 findhonestcare.com